J Thorac Oncol: The efficacy of small cell lung cancer (SCLC) in preventing intracranial irradiation to avoid or not avoid hippocampal structure (HA): a randomized III clinical trial (NCT01780675)

Patients with small cell lung cancer (SCLC) have a high probability of brain metastasis (BM).

Patients with small cell lung cancer (SCLC) have a high probability of brain metastasis (BM).

Therefore, foreign scholars have conducted relevant research and published relevant research results in the Journal of Thoracic Oncology.

The study included 168 patients from 10 centers in the Netherlands and Belgium from April 2013 to March 2018.

The study included 168 patients from 10 centers in the Netherlands and Belgium from April 2013 to March 2018.

A total of 102 patients were included in the analysis when the primary study endpoint was reached, including 46 patients in the PCI group and 56 patients in the HA-PCI group.

Clinical characteristics of the two groups

Clinical characteristics of the two groups

Two groups of HVLT-R rate

Two groups of HVLT-R rate

Cumulative brain metastasis rate in 2 years: PCI group is 20% (95%CI: 12%-29%), and HA-PCI group is 16% (95%CI: 7%-24%).

Cumulative brain metastasis rate in 2 years: PCI group is 20% (95%CI: 12%-29%), and HA-PCI group is 16% (95%CI: 7%-24%).

The incidence of brain metastases in the two groups

The incidence of brain metastases in the two groups

At the time of data cut-off, 102 of the 168 patients had died (49 in the HA-PCI group and 53 in the PCI group).

At the time of data cut-off, 102 of the 168 patients had died (49 in the HA-PCI group and 53 in the PCI group).

Comparison of median OS

 Comparison of median OS

In summary, the prevention of intracranial irradiation of small cell lung cancer (SCLC) did not avoid hippocampal irradiation (HA-PCI) and did not lead to a significant decline in neurocognitive function, and the rate of brain metastasis within 2 years did not increase significantly.

In summary, the prevention of intracranial irradiation of small cell lung cancer (SCLC) did not avoid hippocampal irradiation (HA-PCI) and did not lead to a significant decline in neurocognitive function, and the rate of brain metastasis within 2 years did not increase significantly.

Original source:

José SA Belderbos, Dirk KM De Ruysscher, Katrien De Jaeger, et al.

José SA Belderbos, Dirk KM De Ruysscher, Katrien De Jaeger, et al.
Phase 3 Randomized Trial of Prophylactic Cranial Irradiation With or Without Hippocampus Avoidance in SCLC (NCT01780675).
J Thorac Oncol.
2021 May;16(5):840-849 .
doi: 10.
1016/j.
jtho.
2020.
12.
024.
Leave a message here